financetom
Business
financetom
/
Business
/
Intuit's Guidance Falling Short of Expectations Weighing on Stock Despite In-Line Fiscal Q4 Results, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Intuit's Guidance Falling Short of Expectations Weighing on Stock Despite In-Line Fiscal Q4 Results, UBS Says
Aug 22, 2025 12:14 PM

02:51 PM EDT, 08/22/2025 (MT Newswires) -- Intuit (INTU) posted largely in-line fiscal Q4 results, but Q1 revenue and fiscal 2026 global business solutions revenue guides falling short of expectations are weighing on the stock, UBS Securities said in a Friday research report.

The brokerage said it is positive on Intuit shares on a relative basis because the outlook is prudent and the company has growth drivers outside of a macroeconomic recovery and AI supporting the stock.

UBS stated that fiscal Q4 online revenue growth acceleration to 21% from a year earlier, excluding Mailchimp, was driven by the price hike in tandem with the July product release, product innovation in Money, and mid-market momentum.

UBS said it models a growth of 1% for Desktop and 22% for the online segment, excluding Mailchimp, for fiscal 2026. It does not expect Mailchimp revenue growth to inflect in Q1, but expects nearly 4% growth for the full year.

The company's AI search challenges gained momentum after monday.com's ( MNDY ) print revealed the company recorded an impact. However, Intuit indicated strong traffic growth from enhanced marketing and believes "top brands like its own show up more and have higher conversion rates with AI search queries," according to the note.

UBS reiterated its neutral rating on the stock and cut its price target to $725 per share from $750.

Shares of Intuit fell 5.1% in recent trading.

Price: 661.94, Change: -35.83, Percent Change: -5.13

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Revive Therapeutics Says Key Nerve Agent Countermeasure Study to Continue Through September
Revive Therapeutics Says Key Nerve Agent Countermeasure Study to Continue Through September
Jul 9, 2025
08:38 AM EDT, 07/09/2025 (MT Newswires) -- Revive Therapeutics ( RVVTF ) late on Tuesday said the research study assessing Bucillamine as a potential treatment for nerve agent exposure -- conducted in collaboration with Defence R&D Canada, Suffield Research Centre (DRDC) -- will continue through September. DRDC, part of the Canadian Department of National Defence, is investigating pharmacological compounds, including...
Regulators should limit leverage for 'shadow banks' in core markets, FSB says
Regulators should limit leverage for 'shadow banks' in core markets, FSB says
Jul 9, 2025
LONDON/MILAN (Reuters) -Regulators should consider direct limits on leverage used by non-bank financial firms in core markets as well as measures to curb their size, the Financial Stability Board said on Wednesday in a series of recommendations to make 'shadow banking' safer. Non-bank financial institutions, including hedge funds, private credit providers and insurers accounted for $218 trillion, or just under...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Evolus Partners With Symatese to Distribute Nuceiva in France
Evolus Partners With Symatese to Distribute Nuceiva in France
Jul 9, 2025
08:36 AM EDT, 07/09/2025 (MT Newswires) -- Evolus ( EOLS ) said Wednesday that it has partnered with Symatese to distribute its Botox product Nuceiva in France. Financial terms were not disclosed. Nuceiva, also called botulinum toxin type A, has been approved by the European Commission for the temporary improvement in the appearance of moderate to severe vertical lines between...
Copyright 2023-2026 - www.financetom.com All Rights Reserved